
Yale researchers unveil a groundbreaking 3D-bioprinted synthetic aorta, promising revolutionary advancements in cardiovascular disease treatment and patient care.

Yale researchers unveil a groundbreaking 3D-bioprinted synthetic aorta, promising revolutionary advancements in cardiovascular disease treatment and patient care.

Researchers uncover a mechanism of insulin resistance in obese adolescents, paving the way for potential interventions to prevent type 2 diabetes.

New research suggests intensive blood pressure management may significantly benefit adults aged 80 and older, challenging previous treatment assumptions.

Iron deficiency affects millions globally, especially women, yet remains underdiagnosed. Regular screening can prevent severe health issues and improve lives.

Bose explains her research on vaping among millennial adults who may be at peak lung health, describing the diverse landscape of vaping devices and products.

A recent study reveals that glaucoma surgery significantly improves visual outcomes and reduces medication burden in children with uveitic glaucoma.

Amy Spizuoco, DO, joins the show to discuss her journey as a key opinion leader in dermatology.

New clinical guidelines offer 11 key actions for managing chronic rhinosinusitis, guiding surgery decisions, and improving patient care.

View conference highlights from HCPLive’s coverage of the American Thoracic Society (ATS) International Conference 2025.

A retrospective study indicated the safety and efficacy of FA implants, exhibiting its success in lowering central retina thickness.

Prothena halts birtamimab development after missing key Phase 3 trial endpoints for AL amyloidosis, prompting workforce reductions and cost-cutting measures.

With the priority review acceptance of the Biologics License Application, the FDA has assigned a PDUFA target action date of November 28, 2025.


In this interview, nerandomilast’s safety profile in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) is highlighted.

Discover the critical role of Lp(a) measurement in assessing cardiovascular risk and its potential impact on CVD prevention strategies.

Hosts break down their biggest takeaways and detail their favorite sessions from the AACE 2025 annual meeting.

Recent results have confirmed faricimab’s efficacy, although a small sample size and short follow-up period invite further studies.

New predictive models enhance clinical decision-making for children with pneumonia, identifying severity levels to improve treatment outcomes effectively.

Real-world evidence highlights baricitinib's effectiveness and safety for treating atopic dermatitis and alopecia areata, showing high patient satisfaction and significant improvements.

Attaway reviews data demonstrating the potential benefit of a subspecialty clinic for overcoming current diagnostic and treatment-related challenges for sarcopenia in COPD.

Type 2 macular neovascularization, reductions in outer nuclear layer and central foveal thickness, and intraretinal fluid may indicate higher odds of retinal atrophy.

This interview highlights phase 3 trial data on nerandomilast’s use in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

Despite 2020 guidelines discouraging first-generation antihistamines, ED diphenhydramine use for anaphylaxis and urticaria remained unchanged since 2019.

Prevot describes her research exploring the relationship between OSA severity and abdominal obesity metrics as well as changes in both metrics following CPAP.

Elizabeth Hale, MD, discusses the need to improve awareness and diagnosis of actinic keratosis.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and innovative treatments, in this week's essential news roundup for professionals.

Panretinal photocoagulation and anti-VEGF therapy combined also results in better BCVA and were less likely to require additional treatment within 1 year.

These data from ATS 2025 highlight patients’ real-world outcomes related to treatment of their chronic obstructive pulmonary disease (COPD) with dupilumab.

The FDA approves treprostinil inhalation powder, enhancing treatment options for patients with pulmonary arterial hypertension and interstitial lung disease.

A recent study validated an online tool’s ability to accurately predict peanut allergy; the basophil activation test was the top performer, especially when paired with Ara h 2-sIgE.